LNTHLantheus Holdings, Inc.
Is it growing?
Neither accelerating nor breaking down: earnings up +10% year on year, but operating margin narrowing (−9.3 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +33% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 19.4% now against 28.8% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is LNTH growing?
Lantheus Holdings, Inc. has grown revenue 11% a year over three years and 33% a year over five, with earnings per share compounding at 106%.
Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +33%
Revenue growth, 5-year rate · +11% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +106%
Earnings per share, 3-year rate · revenue +11% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 13
Years of annual history on file · FY2013 to FY2025, as filed
Details›
- Revenue FY2021
- $425M
- Revenue FY2022
- $935M
- Revenue FY2023
- $1.30B
- Revenue FY2024
- $1.53B
- Revenue FY2025
- $1.54B
Annual income statements as filed with the SEC.
Drug Manufacturers, Specialty & Generic
Ranks #5 of 41 by RyuScore